LOREEV XR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Loreev Xr, and what generic alternatives are available?
Loreev Xr is a drug marketed by Almatica and is included in one NDA. There is one patent protecting this drug.
This drug has thirty-five patent family members in thirty countries.
The generic ingredient in LOREEV XR is lorazepam. There are eleven drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the lorazepam profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Loreev Xr
A generic version of LOREEV XR was approved as lorazepam by SANDOZ on April 21st, 1987.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LOREEV XR?
- What are the global sales for LOREEV XR?
- What is Average Wholesale Price for LOREEV XR?
Summary for LOREEV XR
| International Patents: | 35 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 50 |
| Patent Applications: | 4,311 |
| Drug Prices: | Drug price information for LOREEV XR |
| What excipients (inactive ingredients) are in LOREEV XR? | LOREEV XR excipients list |
| DailyMed Link: | LOREEV XR at DailyMed |
Pharmacology for LOREEV XR
| Drug Class | Benzodiazepine |
US Patents and Regulatory Information for LOREEV XR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Almatica | LOREEV XR | lorazepam | CAPSULE, EXTENDED RELEASE;ORAL | 214826-001 | Aug 27, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Almatica | LOREEV XR | lorazepam | CAPSULE, EXTENDED RELEASE;ORAL | 214826-003 | Aug 27, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Almatica | LOREEV XR | lorazepam | CAPSULE, EXTENDED RELEASE;ORAL | 214826-004 | Feb 16, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for LOREEV XR
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
